Biography
Alexander Laemmle, M.D., Ph.D. is a postdoctoral fellow in the Willenbring lab at UCSF.
During his MD-PhD thesis, he focused on the regulation of hepatic cancer cell metabolism upon hypoxic conditions. At that time, he was mainly interested in the question how hepatic cancer cells adapt to hypoxic conditions, thereby promoting cell survival.
During his residency as a pediatrician, he encountered his first urea cycle disorder patients and based on this experience, he became a specialist in pediatric metabolism. After completing his residency, he had the great opportunity to work as a clinical and research fellow in the Division of Metabolism at the Children`s University Hospital in Zurich between 2013 and 2016.
Research Overview
His research interest is dedicated to patients with urea cycle disorders (UCDs). In a significant proportion of patients with UCDs, i.e. ornithine transcarbamylase deficiency (OTCD), there is a severe impairment of liver function with concomitant coagulopathy during the course of the disease. In certain patients there is a strong correlation between metabolic state and liver affection (the higher the ammonia levels, the worse the liver impairment and coagulopathy). The aim is to better characterize and understand the pathophysiology underlying the (probably) ammonia-induced liver impairment. To do so, he is currently reprogramming UCD patient fibroblasts into induced pluripotent stem cells (iPSCs) in order to differentiate them into iPSC-derived hepatocytes and to establish a liver disease model of acute liver failure in UCD patients.